LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Articles
Dimension Therapeutics Inc.
Headquarters:
United States
Website:
N/A
Year Founded:
2013
Status:
Acquired
BioCentury
|
Apr 1, 2020
Deals
AAV tech pays off for Ultragenyx as Daiichi digs into gene therapy
Read More
BioCentury
|
Jan 10, 2020
Clinical News
Gene therapy readout helps Ultragenyx rebound
Read More
BioCentury
|
Dec 4, 2019
Company News
Audentes takeout signals pharma's continued interest in gene therapy manufacturing
Read More
BioCentury
|
Sep 4, 2019
Clinical News
Gene therapy data weigh on Ultragenyx shares
Read More
BioCentury
|
Jun 15, 2018
Company News
Management tracks: JHL, Aclaris, CytomX
Read More
BioCentury
|
Apr 20, 2018
Financial News
New Leaf proposes new $275M fund
Read More
BioCentury
|
Apr 17, 2018
Financial News
New Leaf proposes new $275M fund
Read More
BioCentury
|
Dec 12, 2017
Company News
Management tracks: Achaogen, Minerva
Read More
BioCentury
|
Dec 8, 2017
Product Development
Making of Mepsevii
Why Ultragenyx developed Mepsevii for ultra-rare indication MPS VII
Read More
BioCentury
|
Nov 13, 2017
Company News
Management tracks: PlaqueTec, Biohaven
Read More
Items per page:
10
1 - 10 of 46